The present invention relates to a humanized antibody having excellent stability and high binding capacity to epidermal growth factor receptor (EGFR), more precisely a humanized antibody composed of immunized rabbit originated complementarity determining region (CDR) and human immunoglobulin originated framework region. The humanized antibody of the present invention has high binding capacity to EGF receptor and thus inhibits EGF binding and increases stability, resulting in tumor suppressing effect in vivo. In addition, the humanized antibody minimizes immune response so that it can be effectively used for the diagnosis and treatment of cancer over-expressing EGF receptor.
